202 related articles for article (PubMed ID: 33257571)
21. Inhibition of the prenylation of K-Ras, but not H- or N-Ras, is highly resistant to CAAX peptidomimetics and requires both a farnesyltransferase and a geranylgeranyltransferase I inhibitor in human tumor cell lines.
Lerner EC; Zhang TT; Knowles DB; Qian Y; Hamilton AD; Sebti SM
Oncogene; 1997 Sep; 15(11):1283-8. PubMed ID: 9315095
[TBL] [Abstract][Full Text] [Related]
22. The chaperone SmgGDS-607 has a dual role, both activating and inhibiting farnesylation of small GTPases.
García-Torres D; Fierke CA
J Biol Chem; 2019 Aug; 294(31):11793-11804. PubMed ID: 31197034
[TBL] [Abstract][Full Text] [Related]
23. Cell-permeable CaaX-peptides affect K-Ras downstream signaling and promote cell death in cancer cells.
Klimpel A; Stillger K; Wiederstein JL; Krüger M; Neundorf I
FEBS J; 2021 May; 288(9):2911-2929. PubMed ID: 33112492
[TBL] [Abstract][Full Text] [Related]
24. Elevation of alpha2(I) collagen, a suppressor of Ras transformation, is required for stable phenotypic reversion by farnesyltransferase inhibitors.
Du W; Lebowitz PF; Prendergast GC
Cancer Res; 1999 May; 59(9):2059-63. PubMed ID: 10232587
[TBL] [Abstract][Full Text] [Related]
25. Ras farnesyltransferase inhibition: a novel and safe approach for cancer chemotherapy.
Nammi S; Lodagala DS
Acta Pharmacol Sin; 2000 May; 21(5):396-404. PubMed ID: 11324435
[TBL] [Abstract][Full Text] [Related]
26. A proteomic approach identifies SAFB-like transcription modulator (SLTM) as a bidirectional regulator of GLI family zinc finger transcription factors.
Zhang Z; Zhan X; Kim B; Wu J
J Biol Chem; 2019 Apr; 294(14):5549-5561. PubMed ID: 30782847
[TBL] [Abstract][Full Text] [Related]
27. Protein farnesylation in mammalian cells: effects of farnesyltransferase inhibitors on cancer cells.
Tamanoi F; Gau CL; Jiang C; Edamatsu H; Kato-Stankiewicz J
Cell Mol Life Sci; 2001 Oct; 58(11):1636-49. PubMed ID: 11706990
[TBL] [Abstract][Full Text] [Related]
28. GGTase3 is a newly identified geranylgeranyltransferase targeting a ubiquitin ligase.
Kuchay S; Wang H; Marzio A; Jain K; Homer H; Fehrenbacher N; Philips MR; Zheng N; Pagano M
Nat Struct Mol Biol; 2019 Jul; 26(7):628-636. PubMed ID: 31209342
[TBL] [Abstract][Full Text] [Related]
29. Cell growth inhibition by farnesyltransferase inhibitors is mediated by gain of geranylgeranylated RhoB.
Du W; Lebowitz PF; Prendergast GC
Mol Cell Biol; 1999 Mar; 19(3):1831-40. PubMed ID: 10022870
[TBL] [Abstract][Full Text] [Related]
30. Evolving therapies: farnesyltransferase inhibitors.
Purcell WT; Donehower RC
Curr Oncol Rep; 2002 Jan; 4(1):29-36. PubMed ID: 11734111
[TBL] [Abstract][Full Text] [Related]
31. Contrasting effects of prenyltransferase inhibitors on estrogen-dependent cell cycle progression and estrogen receptor-mediated transcriptional activity in MCF-7 cells.
Doisneau-Sixou SF; Cestac P; Chouini S; Carroll JS; Hamilton AD; Sebti SM; Poirot M; Balaguer P; Faye JC; Sutherland RL; Favre G
Endocrinology; 2003 Mar; 144(3):989-98. PubMed ID: 12586776
[TBL] [Abstract][Full Text] [Related]
32. Farnesyltransferase inhibitor (L-744,832) restores TGF-beta type II receptor expression and enhances radiation sensitivity in K-ras mutant pancreatic cancer cell line MIA PaCa-2.
Alcock RA; Dey S; Chendil D; Inayat MS; Mohiuddin M; Hartman G; Chatfield LK; Gallicchio VS; Ahmed MM
Oncogene; 2002 Nov; 21(51):7883-90. PubMed ID: 12420225
[TBL] [Abstract][Full Text] [Related]
33. Changes in protein prenylation and prenyltransferase activity in the rat seminiferous epithelium during early stages of spermatogenesis.
Dugan JM; Allen CM
Biol Reprod; 1995 Oct; 53(4):958-73. PubMed ID: 8547493
[TBL] [Abstract][Full Text] [Related]
34. Pancreatic cancer cell radiation survival and prenyltransferase inhibition: the role of K-Ras.
Brunner TB; Cengel KA; Hahn SM; Wu J; Fraker DL; McKenna WG; Bernhard EJ
Cancer Res; 2005 Sep; 65(18):8433-41. PubMed ID: 16166322
[TBL] [Abstract][Full Text] [Related]
35. SAFB restricts contact domain boundaries associated with L1 chimeric transcription.
Hong Y; Bie L; Zhang T; Yan X; Jin G; Chen Z; Wang Y; Li X; Pei G; Zhang Y; Hong Y; Gong L; Li P; Xie W; Zhu Y; Shen X; Liu N
Mol Cell; 2024 May; 84(9):1637-1650.e10. PubMed ID: 38604171
[TBL] [Abstract][Full Text] [Related]
36. Inhibition of Ras prenylation: a novel approach to cancer chemotherapy.
Sebti SM; Hamilton AD
Pharmacol Ther; 1997; 74(1):103-14. PubMed ID: 9336018
[TBL] [Abstract][Full Text] [Related]
37. The farnesyl transferase inhibitor (FTI) SCH66336 (lonafarnib) inhibits Rheb farnesylation and mTOR signaling. Role in FTI enhancement of taxane and tamoxifen anti-tumor activity.
Basso AD; Mirza A; Liu G; Long BJ; Bishop WR; Kirschmeier P
J Biol Chem; 2005 Sep; 280(35):31101-8. PubMed ID: 16006564
[TBL] [Abstract][Full Text] [Related]
38. Both farnesyltransferase and geranylgeranyltransferase I inhibitors are required for inhibition of oncogenic K-Ras prenylation but each alone is sufficient to suppress human tumor growth in nude mouse xenografts.
Sun J; Qian Y; Hamilton AD; Sebti SM
Oncogene; 1998 Mar; 16(11):1467-73. PubMed ID: 9525745
[TBL] [Abstract][Full Text] [Related]
39. K-Ras prenylation as a potential anticancer target.
Baranyi M; Buday L; Hegedűs B
Cancer Metastasis Rev; 2020 Dec; 39(4):1127-1141. PubMed ID: 32524209
[TBL] [Abstract][Full Text] [Related]
40. Protein Prenyltransferases and Their Inhibitors: Structural and Functional Characterization.
Marchwicka A; Kamińska D; Monirialamdari M; Błażewska KM; Gendaszewska-Darmach E
Int J Mol Sci; 2022 May; 23(10):. PubMed ID: 35628237
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
